Price
$27.40-4.10%Social Signal Score
Analyst Ratings
40 analysts52-week range
- Last close
- $27.40
- Off 52w high
- -11.0%
- 200-day average
- $27.03
- vs 200-day
- +1.4%
Revenue
$16.58B+21.68%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Albert Bourla
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 75,000
- Beta
- 0.30
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.10
Financials
Revenue
$16.58B+21.7%Net Income
$3.24B+277.0%EBITDA
$5.62B+114.5%Free Cash Flow
$4.80B-7.7%EPS (diluted)
$0.56+330.8%Shares Outstanding (diluted)
5.75B-6.4%Operating Expenses
$6.29BCash & Debt
$14.27BReturn of Capital
$2.45BRevenue by Segment (annual)
$62.58BDividend per Share
$0.43Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $62.58B | $7.77B | $1.36 |
| 2024 | $63.63B | $8.03B | $1.42 |
| 2023 | $59.55B | $2.12B | $0.38 |
| 2022 | $101.17B | $31.37B | $5.59 |
| 2021 | $81.29B | $21.98B | $3.92 |
| 2020 | $41.65B | $9.16B | $1.65 |
| 2019 | $40.91B | $16.03B | $2.92 |
| 2018 | $40.83B | $11.15B | $1.90 |
| 2017 | $52.55B | $21.31B | $3.57 |
| 2016 | $52.82B | $7.21B | $1.18 |
| 2015 | $48.85B | $6.96B | $1.13 |
| 2014 | $49.60B | $9.13B | $1.43 |
| 2013 | $51.58B | $22.00B | $1.71 |
| 2012 | $54.66B | $14.57B | $1.32 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PFE's reported EPS growth of 0.3% a year over 13 years.
- EPS in 5 years
- $1.39
- Implied price
- $24.99
- Return from $27.40
- -1.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $12.42 — -54.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -9.7% | -18.5% | -14.8% | -11.6% | -8.8% | -6.4% |
| -4.7% | -14.0% | -10.1% | -6.7% | -3.8% | -1.2% |
| 0.3% | -9.5% | -5.3% | -1.8% | 1.2% | 4.0% |
| 5.3% | -5.0% | -0.6% | 3.1% | 6.3% | 9.2% |
| 10.3% | -0.4% | 4.1% | 8.0% | 11.3% | 14.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+75.69%Social Signal Score
Mentions (100)
- News (RSS)seekingalpha·8h ago·Neutral
Notable healthcare headlines for the week: Health insurers, Pfizer, and J&J in focus
View source ↗ - News (RSS)fool·9h ago·Neutral
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? Johnson & Johnson's drug-and-device product mix faces off against Pfizer's high-stakes oncology and obesity bets, with a valuation gap that may sway your choice.
View source ↗ - Newsfool.com·14h ago·Positive
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? Johnson & Johnson maintains a diversified business model balancing pharmaceutical innovation with a massive medical technology segment. Pfizer is undergoing a significant transition by investing heavily in oncology and obesity pipelines to offset post-pandemic revenue declines.
View source ↗ - Newsdefenseworld.net·1d ago·Neutral
Top Pharmaceutical Stocks To Add to Your Watchlist – November 19th Eli Lilly and Company, Insmed, Johnson and Johnson, Merck and Co., Inc., AbbVie, Pfizer, and SELLAS Life Sciences Group are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell prescription and other medicines. For investors, they offer exposure to
View source ↗ - News (RSS)seekingalpha·1d ago·Negative
Pfizer: Struggling To Meet Dividend Beyond 2027
View source ↗ - News (RSS)fool·2d ago·Neutral
Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027 Pfizer remains deeply unloved on Wall Street, but it is slowly turning a corner.
View source ↗ - Newszacks.com·2d ago·Neutral
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - News247wallst.com·2d ago·Positive
Pfizer Yields 6.25%. These 3 Dividend Stocks Pay More Than a 1-Year Treasury Bill A risk-free Treasury bill sounds hard to beat, yet three dividend payers in healthcare, tobacco, and pipelines offer more income. Each one also hides a risk that could turn a fat yield into a costly lesson.
View source ↗ - Newszacks.com·3d ago·Neutral
PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies Pfizer's $2.6 billion Starna deal adds three investigational CAR-T programs, strengthening its push into next-generation autoimmune treatments.
View source ↗ - Newszacks.com·3d ago·Neutral
Can New Products and Acquisitions Revive Pfizer's Growth Story? PFE's new launches and acquisitions are reshaping its business, supporting its ambitions to return to growth from 2029.
View source ↗ - Newsfool.com·3d ago·Neutral
Pfizer Will Pay Its 352nd Straight Quarterly Dividend on Dec. 7. Here's What It Would Take to Break the Streak. Pfizer will pay its 352nd consecutive quarterly dividend on Dec. 7, 2026. A patent cliff, a cash-draining acquisition, and major clinical setbacks could threaten the dividend, but all three would likely need to happen to end it.
View source ↗ - News (RSS)zerohedge·3d ago·Negative
…Health Innovation Fund. OHDSI was launched by Janssen, and receives financial support from pharmaceutical companies including Takeda, Janssen, AstraZeneca, Merck and Pfizer.Those relationships do not mean the databases are inherently corrupted or biased, but when organizations involved in processing the data also have commercial interests, independent scrutiny of how the data are handled becomes even more important.The Secrecy of PEDSnetPEDSnet provides a window into how this data pipeline works…
View source ↗ - News (RSS)seekingalpha·4d ago·Neutral
Pfizer: The Patent Cliff Fears Are Overblown
View source ↗ - Newsseekingalpha.com·4d ago·Neutral
Pfizer: The Patent Cliff Fears Are Overblown Pfizer Inc., a Big Pharma player offering a 5.96% dividend yield, remains a controversial choice among long-term retail investors. Most concerns reflect PFE's upcoming patent expiration cycle, which is expected to last about 3 years. However, I believe these fears are overblown given PFE's oncology portfolio, Eliquis, and tafamidis franchise, which delivered strong Q3 performance.
View source ↗ - News (RSS)seekingalpha·4d ago·Positive
Pfizer: Strong Growth Momentum And Attractive Valuation Support A Strong Buy
View source ↗ - News (RSS)fool·5d ago·Neutral
Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters.
View source ↗ - News (RSS)zerohedge·5d ago·Neutral
…. 6, and has since faced "pay-for-play" accusations from former Kennedy adviser Calley Means centered on Ballard (however he incorrectly accused them of representing Pfizer). Brian Ballard says the firm's dealings with her as chief of staff "have been limited and have been the exception, not the rule." Wiles could face a House probe once Democrats take over next year, Rep. Robert Garcia said last week, and her successor, Stephen Miller, has tightened the rules on White House staff meeting lobbyi…
View source ↗ - Newsfool.com·5d ago·Positive
Johnson & Johnson vs. Pfizer: Consistency vs. Johnson & Johnson currently exhibits a stronger overall revenue profile than Pfizer by maintaining consistently higher absolute sales volume across every reported period. Over roughly the last eight quarters, Johnson & Johnson achieved steady quarter-over-quarter revenue growth, while Pfizer experienced a volatile quarter-over-quarter trajectory marked by repeating fluctuations.
View source ↗ - Newsmarketbeat.com·5d ago·Negative
Pfizer CEO Sees Growth Beyond Patent Cliff, Highlights Monthly Obesity Drug Ambitions Pfizer NYSE: PFE expects recently launched medicines and a growing pipeline to help it emerge from a period of patent expirations with high single-digit growth, CEO Albert Bourla said at the Jefferies London Healthcare Conference.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - News (RSS)fool·8d ago·Negative
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027? Novo Nordisk's obesity-drug dominance faces rising rivals, while Pfizer's cheaper valuation and cash flow tell a different story for income-minded investors.
View source ↗ - Newsfool.com·8d ago·Neutral
5 Dividend Stocks With High Yields That Are Safer Than You Might Think A high yield is a sign that investors are worried about a business, but sometimes that concern is overwrought.
View source ↗ - Newsfool.com·8d ago·Neutral
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027? Novo Nordisk A/S maintains a leading position in the high-growth obesity and diabetes treatment markets. Pfizer offers a highly diversified product portfolio and significant free cash flow generation.
View source ↗ - Newsfool.com·9d ago·Neutral
Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now? Investors are downbeat on Pfizer, at least in part due to concerns about innovation and patent expirations. The company continues to invest in new drugs, but innovation can't be scheduled.
View source ↗ - Newszacks.com·9d ago·Positive
Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit? PFE shares fell despite the company beating Q3 estimates and raising guidance. Explore its growth drivers, pipeline potential, patent risks & attractive valuation.
View source ↗ - News (RSS)seekingalpha·10d ago·Negative
Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug
View source ↗ - News (RSS)zerohedge·10d ago·Negative
…ennedy aide Calley Means, who told Joe Rogan that Wiles said "I need the sugar industry money," and pollster Mark Mitchell, who said Wiles warned him off criticizing Pfizer. A Wiles spokesperson called the accusations "outrageous, defamatory, and provably false," and Ballard Partners, her former lobbying firm, says it has never represented Pfizer."We've already been looking at Susie Wiles. With all of this new information that's come out, it is incredibly serious ... it's not just going to be Ov…
View source ↗ - News (RSS)zerohedge·12d ago·Neutral
Susie Wiles 'Pay-For-Play' Scandal Goes Nuclear With New Pfizer Accusations; White House Responds Susie Wiles 'Pay-For-Play' Scandal Goes Nuclear With New Pfizer Accusations; White House Responds Pollster Mark Mitchell, an adviser to Vice President JD Vance, says Susie Wiles, Trump's former chief of staff, warned him off criticizing Pfizer, which he called her old lobbying firm's "number one client."Before she ran Donald Trump's 2024 campaign and then his White House, Wiles spent nearly a decade…
View source ↗ - News (RSS)fool·12d ago·Neutral
Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock This surprising healthcare stock has been outperforming the markets this year.
View source ↗ - Newsfool.com·12d ago·Negative
Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock Pfizer's recently launched and acquired products have been generating impressive growth. The stock is up big this year, but its valuation remains modest based on analyst expectations.
View source ↗ - Newsfool.com·13d ago·Negative
Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028 Pfizer acquired a promising GLP-1 drug last year through its purchase of Metsera. It plans to eventually launch both weekly and monthly versions of the treatment.
View source ↗ - News (RSS)zerohedge·14d ago·Neutral
…ery single industry we're fighting against right now to this day." Later in the episode the show pulled up what Means said was the client list on Fabrizio's website: Pfizer, PhRMA, Philip Morris, Procter & Gamble, R.J. Reynolds and Dow Chemical among them. On school lunch reform, Means said, Fabrizio was "getting paid by Pepsi and giving political analysis that the juice isn't worth the squeeze." Calley Means, senior advisor at Health and Human Services (HHS) and co-founder of TrueMed, at the Se…
View source ↗ - News (RSS)seekingalpha·14d ago·Neutral
Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focus
View source ↗ - News (RSS)fool·15d ago·Neutral
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.
View source ↗ - Newsfool.com·15d ago·Negative
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials Eli Lilly is the leader in the GLP-1 weight-loss space, with Novo Nordisk working hard to regain lost market share. Pfizer had to drop its GLP-1 drug candidate, but quickly pivoted by acquiring a new GLP-1 drug still in development.
View source ↗ - PodcastCompound And Friends·16d ago·Negative
… going to be in the headline three months from now, so that my clients are aware when they're making needs investments. What will happen is the big pharma companies, Pfizer, Bristol Myers, Eli Lilly, they'll go into Washington, they'll lobby. And they'll say, why don't you do it on Medicaid, which is a smaller portion? And then what you do is you start isolating out, Gilead, which has a high AIDS Medicaid population, where vertex, which is my favorite healthcare company in the world. And to say,…
View source ↗ - News (RSS)fool·17d ago·Positive
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than many expect.
View source ↗ - News (RSS)fortune·17d ago·Neutral
Pfizer promotes its first female CFO as women’s share of top finance jobs slips Cecile Guegan’s promotion comes as women’s share of global CFO appointments fell to 20% in the first three quarters of 2026.
View source ↗ - News (RSS)seekingalpha·17d ago·Neutral
Pfizer: The Portfolio Transformation Is Gaining Momentum
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Pfizer: The Portfolio Transformation Is Gaining Momentum Pfizer remains a Buy as its robust pipeline and strategic acquisitions drive portfolio adaptation ahead of the LOE cliff. PFE delivered a double-beat Q3, raised 2026 guidance, and posted strong non-COVID product growth, offsetting COVID-19 revenue declines. Major acquisitions combined with aggressive cost savings position PFE for strong post-LOE performance and diversification.
View source ↗ - Newsseekingalpha.com·18d ago·Neutral
Pfizer Q3: The Street Is Pricing In Too Much Deceleration For This 5.7% Yield Pfizer delivered Q3 2026 revenue of $16.58B and adjusted EPS of $0.87, beating consensus and raising full-year guidance for the second time. PFE's non-COVID portfolio grew 7% operationally, with launched and acquired products up 32%, offsetting steep COVID-related declines. Management now guides 2026 revenue to $62–$64B and adjusted EPS to $2.95–$3.05, with cost savings and a 5.73% dividend yield well covered by FCF.
View source ↗ - Newsfool.com·18d ago·Neutral
Pfizer: 3 Key Takeaways for Long-Term Investors Pfizer raised 2026 revenue guidance to $62 billion to $64 billion. Launched and acquired products achieved 32% operational revenue growth in Q3.
View source ↗ - Newsbenzinga.com·18d ago·Neutral
Amazon, Pfizer, Eaton And A Financial Stock On CNBC's ‘Final Trades' On CNBC's “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Amazon.com, Inc. (NASDAQ:AMZN).
View source ↗ - Newsmarketbeat.com·18d ago·Negative
Pfizer Q3 Earnings Call Highlights Pfizer NYSE: PFE reported third-quarter 2026 revenue of $16.6 billion and raised its full-year outlook, citing growth in non-COVID products, contributions from launched and acquired medicines, and continued cost-control efforts.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Pfizer Inc. (PFE) Q3 2026 Earnings Call Transcript Pfizer Inc. ( PFE ) Q3 2026 Earnings Call November 3, 2026 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO Cecile Guegan - Interim CFO & Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development Alexandre de Germay - Executive VP & Chief International Commercial Officer Aamir Malik - Executive VP & Chief U.S. Commercial Office…
View source ↗ - PodcastCompound And Friends·18d ago·Neutral
…nd they are decided on excited about vertical SaaS, which is what toes this. But they sort of own this vertical. They have competitors like Clover, which is owned by Pfizer. Pfizer, actually, I'm guessing they had a good quarter. The stock was up 14% or so today. Yeah, and then the other one is Block, which is Square, which I guess is a competitor, but I don't know. They're supportive. Everywhere you go is, everywhere you go is toast. And the revenue growth is here. They are now, they're telling…
View source ↗ - News (RSS)seekingalpha·19d ago·Neutral
Midday Need to Know: Trump signals end to Israel aid, Pfizer raises 2026 outlook & more
View source ↗ - News (RSS)seekingalpha·19d ago·Neutral
Pfizer Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - News (RSS)investing·19d ago·Neutral
Pfizer Q3 2026 slides: 32% growth in new products, guidance raised
View source ↗ - News (RSS)rte·19d ago·Negative
Pfizer raises 2026 forecasts after strong Q3 results Pfizer has today raised its full-year profit and revenue forecasts as strong demand for its recently acquired cancer drug Padcev and blockbuster blood thinner Eliquis led to higher-than-expected third-quarter results.
View source ↗ - News (RSS)fool·19d ago·Positive
Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally? The healthcare stock may finally have the catalyst that it needs to take off before the end of the year.
View source ↗ - News (RSS)ft·19d ago·Negative
Pfizer predicts higher profits as new drugs offset falling sales of Covid products Pharma group posts 7% rise in revenue from non-Covid medicines including blockbuster blood thinner
View source ↗ - News (RSS)zerohedge·19d ago·Neutral
…ed by $2.5 billion of committed secured debt financing, while Apollo said new lending hit a record in the third quarter even as adjusted earnings missed, and ADM and Pfizer boosted their 2026 outlooks. Meta is wrapping up investor meetings today for its dollar and euro bond sale, after Monday's $27.9 billion investment-grade haul. Brookfield and QIA will invest £2.5 billion in a Drax data center, and Bridgepoint shareholders are selling about 25 million shares in an accelerated bookbuild. Other …
View source ↗ - Newszacks.com·19d ago·Neutral
Pfizer (PFE) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·19d ago·Positive
PFE Beats Q3 Earnings & Sales Estimates, Raises 2026 Guidance Pfizer beats third-quarter earnings and revenue estimates, driven by strong non-COVID product sales, and increases its 2026 guidance.
View source ↗ - Newsfool.com·19d ago·Positive
Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction Revenue was flat at $16.6 billion, with COVID and Prevnar sales falling while Eliquis, Padcev, Vyndaqel, Nurtec, and Lorbrena grew. Pfizer raised its full-year revenue and adjusted EPS guidance.
View source ↗ - Newszacks.com·19d ago·Positive
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates Pfizer (PFE) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.87 per share a year ago.
View source ↗ - Newsfool.com·19d ago·Positive
Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally? Pfizer's numbers were strong in its most recent quarter, with both its top and bottom lines coming in better than analyst forecasts. The company experienced 32% growth from launched and acquired products, highlighting its underrated growth potential.
View source ↗ - Newswsj.com·19d ago·Negative
Pfizer Raises Forecast on Momentum With New Products Pfizer boosted its guidance for the year, citing momentum in newly-launched and acquired products that helped offset declining sales for its Covid-19 vaccine and treatments.
View source ↗ - Newscnbc.com·19d ago·Positive
Pfizer hikes full-year outlook, taps company veteran as new CFO Pfizer reported third-quarter results that topped estimates and hiked its full-year outlook, citing its "strong year-to-date performance" and ongoing cost cuts. Pfizer also announced that Cecile Guegan, who has held various finance leadership roles at the company over the last two decades, stepped in as chief financial officer this month.
View source ↗ - Newsbusinesswire.com·19d ago·Neutral
Pfizer Appoints Cecile Guegan as Chief Financial Officer NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. Cecile has served as interim Chief Financial Officer since August 16, 2026, steering the company's financial operations, execution and strategic planning. “Cecile is an exceptional finance leader who knows our company and i…
View source ↗ - Newsbenzinga.com·19d ago·Neutral
Top Wall Street Forecasters Revamp Pfizer Expectations Ahead Of Q3 Earnings Pfizer Inc. (NYSE:PFE) will release its third quarter earnings report before the opening bell on Tuesday, Nov. 3.
View source ↗ - Newsbenzinga.com·19d ago·Neutral
Pfizer, Apple And 3 Stocks To Watch Heading Into Tuesday With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
View source ↗ - News (RSS)zerohedge·20d ago·Neutral
…: RBA decision, ECB's Radev, Moulin, Kocher, Dolenc, Nagel, Sleijpen and Escriva speak, BoC’s Macklem and Rogers speakEarnings: AMD, Amgen, Arista Networks, Shopify, Pfizer, Eaton, Marathon Petroleum, Intesa Sanpaolo, Booking, Energy Transfer, Ferrari, Apollo, Bayer, Keurig Dr Pepper, BlockOther: UK Chancellor Healey and Treasury ministerial team answer oral questions in the House of CommonsWednesday November 4 Data: US October ISM services, ADP report, September trade balance, China October Rat…
View source ↗ - News (RSS)investing·20d ago·Neutral
Pfizer stock setup analysis ahead of Tuesday earnings
View source ↗ - News (RSS)zerohedge·20d ago·Neutral
…: RBA decision, ECB's Radev, Moulin, Kocher, Dolenc, Nagel, Sleijpen and Escriva speak, BoC's Macklem and Rogers speakEarnings: AMD, Amgen, Arista Networks, Shopify, Pfizer, Eaton, Marathon Petroleum, Intesa Sanpaolo, Booking, Energy Transfer, Ferrari, Apollo, Bayer, Keurig Dr Pepper, BlockOther: UK Chancellor Healey and Treasury ministerial team answer oral questions in the House of CommonsWednesday November 4Data: US October ISM services, ADP report, September trade balance, China October Rati…
View source ↗ - News (RSS)fool·22d ago·Neutral
Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real? Pfizer's post-COVID comeback is still only in the early stages.
View source ↗ - Newsfool.com·22d ago·Neutral
Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real? Pfizer shares are up amid bullish sentiment about the pharmaceutical company's turnaround efforts. The upcoming loss of patent exclusivity for several blockbuster drugs could prevent a full recovery into 2029.
View source ↗ - News247wallst.com·23d ago·Negative
$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends Dividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while you sleep. But not every yield here is as safe as it looks.
View source ↗ - Newsseekingalpha.com·23d ago·Negative
Pfizer: Reality Check Ahead Of Earnings Pfizer is downgraded from 'Buy' to 'Hold' as analyst sentiment turns increasingly bearish and growth prospects dim. Consensus expects declining revenue and EPS through 2029, with skepticism about management's optimistic growth projections and pipeline potential. Cost-cutting efforts and pipeline updates, including anti-obesity drugs from Metsera, are critical but unlikely to offset looming patent cliffs.
View source ↗ - News247wallst.com·23d ago·Neutral
Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe? Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow.
View source ↗ - Newszacks.com·24d ago·Neutral
Exploring Analyst Estimates for Pfizer (PFE) Q3 Earnings, Beyond Revenue and EPS Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
View source ↗ - Newszacks.com·25d ago·Positive
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why Pfizer (PFE) closed at $29.45 in the latest trading session, marking a -1.17% move from the prior day.
View source ↗ - Newszacks.com·25d ago·Neutral
Pfizer Stock Ahead of Q3 Earnings: To Buy or Not to Buy? Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.
View source ↗ - Newsbenzinga.com·26d ago·Neutral
Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients Pfizer Inc. (NYSE:PFE) on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as a monotherapy.
View source ↗ - Newsbusinesswire.com·27d ago·Negative
Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC) with homologous recombination repair (HRR) gene mutations, including b…
View source ↗ - News (RSS)zerohedge·28d ago·Positive
…son via Modernity, In a packed courtroom in Leeuwarden, the official COVID story is being put on trial as Dutch plaintiffs demand personal liability from Bill Gates, Pfizer CEO Albert Bourla, former Prime Minister Mark Rutte and others for what their lawyer calls a coordinated global deception. The civil case, filed in 2023, alleges the mRNA injections functioned as lethal biological weapons rolled out through unlawful public deception tied to the World Economic Forum's Great Reset. Two of the o…
View source ↗ - News (RSS)zerohedge·28d ago·Positive
Appeals Court Throws Out Alex Berenson's Case Against Pfizer Executives Appeals Court Throws Out Alex Berenson's Case Against Pfizer Executives Authored by Zachary Stieber via The Epoch Times, A federal appeals court has thrown out a lawsuit from independent journalist Alex Berenson accusing Pfizer executives of pressuring Twitter to censor him because of his comments opposing COVID-19 vaccines. In a file image from video, Alex Berenson speaks during an interview with The Epoch Times. The Epoch …
View source ↗ - News (RSS)seekingalpha·29d ago·Positive
Pfizer sees strong response for pediatric pneumonia vaccine in mid-stage trial
View source ↗ - News (RSS)investing·29d ago·Neutral
Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
View source ↗ - Newsgurufocus.com·29d ago·Neutral
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 [url="]Pfizer Inc.[/url] (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study ([url="]NCT06524414[/url]) for its investigational 2
View source ↗ - Newsbusinesswire.com·29d ago·Neutral
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability compara…
View source ↗ - Newsfool.com·29d ago·Negative
Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem Pfizer's financial results have exceeded expectations in recent quarters. The company's newer and acquired products, as well as several that could earn approval in the coming years, will help it overcome patent cliffs.
View source ↗ - Newsfool.com·30d ago·Positive
Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb? Pfizer's dividend yield ranks among the highest in the healthcare sector and S&P 500. Bristol Myers Squibb maintains a more comfortable payout ratio than Pfizer, though.
View source ↗ - News (RSS)fool·30d ago·Neutral
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer They definitely matter... up to a point.
View source ↗ - News (RSS)fool·31d ago·Positive
Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.
View source ↗ - Newsfool.com·31d ago·Neutral
Bristol Myers Squibb vs. Pfizer: Consistency vs. Pfizer currently generates a higher volume of absolute revenue, while Bristol Myers Squibb displays a more consistent baseline without the recent negative fluctuations seen by the former. Over the last eight quarters, Pfizer experienced fluctuating quarter-over-quarter results with multiple periods of year-over-year contraction, whereas Bristol Myers Squibb maintained a steadier trajectory characterized by continuous year-over-year growth.
View source ↗ - News247wallst.com·31d ago·Negative
Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before you chase the bigger payout, the coverage numbers behind each dividend tell a very different story.
View source ↗ - News (RSS)zerohedge·31d ago·Negative
…lves and their products to the American public. In the last handful of years, Weber Shandwick's clients have included the bulk of the global vaccine giants including Pfizer, Moderna, GSK, Sanofi, Novartis, and Eli Lilly. But when he's not raking in oodles of cash repping corporate America, Leslie also takes on some unpaid healthcare positions as further leverage to market his lucrative pharma clients, such as heading the board of the NIH Clinical Center Research Hospital Board. The board met on …
View source ↗ - Newszacks.com·33d ago·Neutral
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing In the latest trading session, Pfizer (PFE) closed at $30.11, marking a +2.28% move from the previous day.
View source ↗ - Newszacks.com·33d ago·Neutral
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsfool.com·34d ago·Positive
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally? A rotation may be taking place, out of tech stocks and into healthcare. Pfizer is one of the more attractive-looking healthcare stocks to own right now, based on its valuation and dividend payments.
View source ↗ - Newszacks.com·34d ago·Neutral
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch Pfizer's Q3 results will shed light on its non-oncology portfolio, as demand trends, pricing pressure and vaccine sales shape performance across key therapies.
View source ↗ - News247wallst.com·34d ago·Positive
Pfizer's Dividend Freeze Raises a Bigger Question About Its Cash Flow Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline numbers suggest.
View source ↗ - Newsfool.com·35d ago·Neutral
Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway. Not every company is at risk.
View source ↗ - News (RSS)zerohedge·36d ago·Neutral
…r, after most eligible young people had already received two doses. An Oxford analysis found an eight-fold risk of myocarditis in under-40s within a week of a second Pfizer dose and a 44-fold risk after Moderna. Hong Kong reported a one-in-3,000 risk in adolescent boys after a second dose and switched to a single-dose policy. A Thai study of teenagers found 29% with signs of heart disturbance after a second Pfizer dose. No comparable reckoning has followed the delayed disclosure. In Australia, F…
View source ↗ - News (RSS)fool·37d ago·Negative
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe? Pfizer's dividend yield is attractive, but investors need to know if it can maintain it.
View source ↗ - Newsfool.com·37d ago·Negative
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe? The drugmaker faces significant patent cliffs this year and next. But it also has a robust pipeline of new drugs in development.
View source ↗ - News (RSS)fool·38d ago·Positive
2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends Verizon and Pfizer pay generous dividends, and each has a different path to growth. Here's how income investors can lock in yield before year-end.
View source ↗ - News (RSS)fool·38d ago·Negative
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.
View source ↗
Earnings
Tue, Feb 2(in 2 months)
Consensus estimate $0.69 per share
Typical surprise +18.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$0.87 vs $0.73beat
- Tue, Aug 4$0.77 vs $0.68beat
- Tue, May 5$0.75 vs $0.72beat
- Tue, Feb 3$0.66 vs $0.57beat
- Tue, Nov 4$0.87 vs $0.63beat
- Tue, Aug 5$0.78 vs $0.58beat
Estimates and results for PFE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PFE officers and directors.
- Bought
- $3.0m
- Sold
- $135k
3 trades
2 trades
- Bourla Albertbought
- Damico Jennifer B.sold
- Blaylock Ronald Ebought
- Buckley Mortimer Jbought
- Damico Jennifer B.sold
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (14d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Sell$15,001 - $50,000
- Carol Devine Millerhouse · WV01 · disclosed Aug 14, 2026 (522d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (36d later)Buy$1,001 - $15,000
- Michael Rullihouse · disclosed Aug 10, 2026 (622d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (119d later)Sell$50,001 - $100,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jul 16, 2026 (38d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (26d later)Sell$1,001 - $15,000
- Susan Margaret Collinssenate · ME · disclosed Mar 26, 2026 (51d later)Buy$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2026 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$15,001 - $50,000
- French Hillhouse · AR02 · disclosed Jan 23, 2026 (23d later)Sell$100,001 - $250,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (210d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 12, 2026 (24d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (27d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (18d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
